AAN 2021 | Phase III trials of tolebrutinib in relapsing-remitting and progressive MS

Anthony Traboulsee, MD, University of British Columbia Hospital, Vancouver, Canada, talks on upcoming Phase III trials of tolebrutinib for multiple sclerosis (MS). Tolebrutinib is a novel selective Bruton tyrosine kinase inhibitor under investigation in relapsing-remitting, secondary progressive and primary progressive settings. It is one of the most highly central nervous system (CNS)–penetrant drugs in its class, making it a promising option for the treatment of progressive disease via activity on CNS-resident immune cells. Dr Traboulsee also talks on how tolebrutinib would fit into MS treatment regimens. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.